RPE65 and Leber congenital amaurosis: However, while the AAV vector-based gene therapy drug was successful in treating patients with confirmed biallelic RPE65 mutation-associated Leber Congenital Amaurosis (LCA) and was approved by the FDA in 2017 [35], clinical trials of gene therapy on XLRS patients have shown unpromising results.